You are here: Industry Insights > Mallinckrodt

News List

Mallinckrodt to Sell CDMO BioVectra for $250M contractpharma
September 12, 2019
BioVectra will continue to supply an API for Mallinckrodt's specialty brands business under a long-term deal.
Mallinckrodt investors stream for the exits as opioid-tied bankruptcy talk mounts fiercepharma
September 08, 2019
Shares of the U.K. drugmaker careened to $1.44 per share in late trading Wednesday on the heels of a Bloomberg report that Mallinckrodt hired two firms to walk through bankruptcy options as a federal opioid lawsuit roundup approaches trial next month.
Mallinckrodt Announces Top-Line Results from Terlipressin Trial americanpharmaceuticalreview
August 16, 2019
Mallinckrodt announced positive top-line results from its pivotal Phase 3 CONFIRM clinical study evaluating the efficacy and safety of terlipressin in 300 adults with hepatorenal syndrome type 1 (HRS-1).
Humana calls Mallinckrodt's Acthar a 'billion-dollar golden goose' in $700M fraud lawsuit fiercepharma
August 13, 2019
Mallinckrodt is getting burned on all sides as federal prosecutors scope out the drugmaker’s controversial H.P. Acthar Gel marketing and price hikes. Now, one of the largest U.S. insurers is looking to pile on.
Mallinckrodt postpones split-up plan as opioid lawsuits cloud spinoff's future fiercepharma
August 07, 2019
Mallinckrodt thought it had a plan to rehabilitate its image, rid itself of low-performing products and banish at least some of its legal problems. But now it's put that plan on hold.
Mallinckrodt, Silence Therapeutics Enter RNAi Alliance contractpharma
July 24, 2019
Aims to develop and commercialize RNAi therapeutics for complement-mediated diseases.
Mallinckrodt partners with Silence Therapeutics for RNAi drugs pharmaceutical-technology
July 22, 2019
Mallinckrodt has partnered with Silence Therapeutics for the development and commercialisation of RNA interference (RNAi) drugs to treat patients with complement-mediated diseases.
Mallinckrodt, Silence Therapeutics Announce Collaboration americanpharmaceuticalreview
July 19, 2019
Mallinckrodt and Silence Therapeutics announced a collaboration that will allow the companies to develop and commercialize RNAi drug targets designed to inhibit or 'silence' the complement cascade ...
Mallinckrodt files lawsuit against US health agencies pharmaceutical-technology
May 23, 2019
Mallinckrodt has filed a lawsuit against the US Health and Human Services (HHS) and Centers for Medicare and Medicaid Services (CMS) over a decision to change Medicaid rebates for its Acthar Gel.
Mallinckrodt Completes Wisconsin Mfg. Facility contractpharma
April 26, 2019
Mallinckrodt has completed the expansion of its operations and manufacturing facility for the investigational StrataGraft regenerative skin tissue, in Madison, WI. Stratatech, a Mallinckrodt company ...

Previous page 1 2 3 4 5 Next page